Title |
French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia
|
---|---|
Published in |
Experimental Hematology & Oncology, December 2012
|
DOI | 10.1186/2162-3619-1-39 |
Pubmed ID | |
Authors |
Pascale Trioche, Brigitte Nelken, Gérard Michel, Isabelle Pellier, Arnaud Petit, Yves Bertrand, Pierre Rohrlich, Claudine Schmitt, Nicolas Sirvent, Patrick Boutard, Geneviève Margueritte, Brigitte Pautard, Stéphane Ducassou, Dominique Plantaz, Alain Robert, Caroline Thomas, Kristell Desseaux, Sylvie Chevret, André Baruchel |
Abstract |
Clofarabine alone or in combination with cyclophosphamide and etoposide has shown a good efficacy and a tolerable toxicity profile in previous studies of children with relapsed or refractory leukaemia. This report describes a retrospective study of 38 French patients who received clofarabine as a monotherapy or in combination for relapsed or refractory acute lymphoblastic leukaemia (ALL) outside of clinical trials after marketing authorization. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 18 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 22% |
Student > Bachelor | 3 | 17% |
Other | 3 | 17% |
Student > Master | 2 | 11% |
Lecturer | 1 | 6% |
Other | 3 | 17% |
Unknown | 2 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 50% |
Business, Management and Accounting | 1 | 6% |
Nursing and Health Professions | 1 | 6% |
Economics, Econometrics and Finance | 1 | 6% |
Agricultural and Biological Sciences | 1 | 6% |
Other | 2 | 11% |
Unknown | 3 | 17% |